Drugs / Ropeginterferon alpha-2b
Ropeginterferon alpha-2b
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01949805 | Sep 2013 → Jul 2016 | acquired polycythemia vera | AOP Orphan Pharmaceuticals AG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ropeginterferon alpha-2b | “We characterized the activity of ropeginterferon alpha-2b, a novel form of interferon-alpha recently shown to be safe and efficacious in polycythemia vera.” PMID 30287855 ↗ Oct 2018 |
| Action | Inhibit | “Ropeginterferon was able to inhibit the proliferation of the HEL, UKE-1, and UT-7 JAK2-mutant cell lines” PMID 30287855 ↗ Oct 2018 |
| Modality | Protein / enzyme biologic | “AOP2014 is a next generation pegylated interferon (Peg-P-IFN-alpha-2b), with the addition of proline in the N-terminal end.” NCT01949805 ↗ |
| Route | Subcutaneous | “Pegylated interferon alpha 2b given Q2W as SC injection” NCT01949805 ↗ |